This summary of the $5 1 0 ( \mathsf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

1. Submitter name, address, contact

Olympus Life and Material Science Europa GmbH Lismeehan, O'Callaghan's Mills Co. Clare, Ireland

U.S. Telephone: 469-230-0959   
U.S. Fax: 972-317-7861   
Telephone: 011-353-65-683-1100

Contact Person: Stephanie G. Schwartz

Date Prepared: April 25, 2007

Device name

Proprietary Name: Olympus D-Dimer Reagent (OSR6x135) Olympus D-Dimer Calibrator (ODR3033) Olympus D-Dimer Control (ODC0029)

Common Name: D-Dimer Reagent, Calibrator and Control

Classification Name: Fibrinogen/fibrin degradation products assay

Predicate device

Reagent: Calibrator Control

Submitted (K030740 & K002706)

Device description

In this Olympus procedure, the decrease in light intensity transmitted (increase in absorbance) through particles suspended in solution is as a result of complexes formed during the immunological reaction between the D-Dimer of the patient serum and the anti-human D-Dimer antibodies coated on the latex particles

5. Intended use

System reagent for the quantitative determination of D-Dimer in human plasma on Olympus analyzers

The Olympus D-Dimer Calibrator is designed to provide suitable calibration levels for Olympus analyzers employing the immunoturbidimetric assays for D-Dimer determinations

The Olympus D-Dimer Control is a lyophilized human control. These assayed controls are designed to monitor the accuracy and precision of the quantitative Olympus D-Dimer reagents.

# 510(k) Summary

The assigned 510(k) number is:

6.

The following Tables compare the new Olympus D-Dimer Test System with the Roche Tina-Quant® D-Dimer Test System.

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus D-Dimer Test System</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Reagent for the quantitativedetermination of D-Dimer in humanplasma</td><td rowspan=1 colspan=1>Assay for quantitative determination ofD-Dimer in human plasma</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Another Commercially available assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Citrate and Lithium Heparin Plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Methodology</td><td rowspan=1 colspan=1>Latex enhanced Immunoturbidimetric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Monoclonal anti human D-Dimermouse antibodies</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Latex Particle</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent storage form</td><td rowspan=1 colspan=1>LiquidOn -board storage</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Handling</td><td rowspan=1 colspan=1>R1 Ready for useR2: Mix before placing on instrumentand at weekly intervals thereafter</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator and ControlConstituents</td><td rowspan=1 colspan=1>Single</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator and ControlMaterial</td><td rowspan=1 colspan=1>Human Origin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Catibrator Storage form</td><td rowspan=1 colspan=1>Calibrator 1 : Liquid ready to useCalibrator 2 : Lyophilized Powder</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>6 points</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Quality Controls</td><td rowspan=1 colspan=1>2 Levels</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Control Storage Form</td><td rowspan=1 colspan=1>Lyophilized Powder</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>&lt; 0.5 μg FEU/mL</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus D-Dimer Test System</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Instrument required</td><td rowspan=1 colspan=1>Olympus AU400/400e, 600/640/640eand 2700/5400</td><td rowspan=1 colspan=1>Roche/Hitachi analyzers.Calibrator and control can also be usedwith Roche Cobas Integra analyzers.</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>System reagent for the quantitativedetermination of D-Dimer in humanplasma on OLYMPUS analyzers</td><td rowspan=1 colspan=1>Immunoturbidimetric assay for the invitro quantitative determination of fibrindegradation products including D-Dimer and X-oligomers in humanplasma on Roche automated clinicalchemistry analyzers.</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>Traceable to an in-house MasterCalibrator and aligned with anothercommercially available test system</td><td rowspan=1 colspan=1>The Roche Tina-Quant® D-Dimermethod was calibrated against theAsserachrom D-Dimer method</td></tr><tr><td rowspan=1 colspan=1>Reagent On Board Stability</td><td rowspan=1 colspan=1>30 days on board</td><td rowspan=1 colspan=1>28 Days on board</td></tr><tr><td rowspan=1 colspan=1>Calibrator Open VialStability</td><td rowspan=1 colspan=1>•1 day @ 15 - 25°√ 28 days @ 2 - 8°C. 30 days @ -20°C</td><td rowspan=1 colspan=1>1 day @ 15 -25</td></tr><tr><td rowspan=1 colspan=1>Control Open vial Stability</td><td rowspan=1 colspan=1>. 1 day @ 15 - 25°C28 days @ 2 - 8°C• 30 days @ -20°C</td><td rowspan=1 colspan=1>1 day @ 15 - 25°C14 days @ 2 - 8°C</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Not Specified</td></tr></table>

# 510(k) Summary

The assigned 510(k) number is:

<table><tr><td rowspan=1 colspan=3>Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Olympus D-Dimer Test System</td><td rowspan=1 colspan=1>Predicate System</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>AU400/400eSample      Total CV%1              9.442             7.993             2.48AU600/640/640eSample      Total CV%1              9.142             7.953              3.02AU2700/5400Sample       Total CV%1             8.172             4.443              2.52</td><td rowspan=1 colspan=1>Sample      Total CV%1             6.5N3             8.33.2</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>0.15 - 8.00 μg FEU/mL</td><td rowspan=1 colspan=1>0.15 - 9.0 μg FEU/mL</td></tr><tr><td rowspan=1 colspan=1>Analytical Sensitivity</td><td rowspan=1 colspan=1>0.08 μg FEU/mL</td><td rowspan=1 colspan=1>0.04 μg FEU/mL</td></tr><tr><td rowspan=1 colspan=1>Method Comparison (LinearRegression)</td><td rowspan=1 colspan=1>Intercept     0.079Slope        1.010R^2}$            0.996Range       0.28-7.53 μg FEU/mL</td><td rowspan=1 colspan=1>Intercept     0.06Slope        0.87R^{22}$            0.755Range       0.08-4.55 μg FEU/mL</td></tr><tr><td rowspan=1 colspan=1>Interfering Substances</td><td rowspan=1 colspan=1>AU400/400e, 600/640/640e &amp;2700/5400Interference less than 10%Bilirubin: up to 40 mg/dL BilirubinHemolysis: up to 500 mg/dLHemolysateRheumatoid Factor: up to 100lU/mLHeparin: up to 1.5 IU/mLAU400/400e &amp; 600/640/640eInterference less than 10%Lipemia: up to 1000 mg/dL Intralipid2700/5400Interference less than 10%Lipemia: up to 700 mg/dL Intralipid</td><td rowspan=1 colspan=1>Roche Analyzerswithin ± 10% of initial valueBilirubin up to 20 mg/dL BilirubinHemolysis: up to 500 mg/dLHemoglobinRheumatoid Factor: &lt; 100 IU/mLHeparin: &lt; 1.5 IU/mLLipemia: up to 1500 mg/dLTriglyceride Concentration</td></tr></table>

Stephanie Schwartz   
Olympus Life & Material Science Europa GMBH c/o Olympus America, Inc.   
3131 West Royal Lane   
Irving, Texas 75063

Re: k070453 Trade/Device Name: Olympus D-Dimer Reagent, Olympus D-Dimer Calibrator, Olympus D-Dimer Control Regulation Number: 21 CFR 864.7320 Regulation Name: Fibrinogen/fibrin degradation products assay Regulatory Class: Class II Product Code: GHH Dated: April 25, 2007 Received: April 30, 2007

Dear Ms. Schwartz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150, or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

![](images/fc1fa2a83f29f71d8efa1717ae97a8207000371df21c8f4f353d9b1cb21d17b8.jpg)

Robert L. Becker, Jr., MD, PhD   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device Evaluation   
and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K070453

Device Name: Olympus D-Dimer Test System

Indications for Use:

System reagent or the quantitative determination of D-Dimer in human plasm OLYMPUS analyzers.

An and in monitoring therapy for disseminated intravascular coagulation.

(Pat i on Sr ) AND/OR (ver-The-Couter luse)

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Muy hine Lrutitin Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety 510(Kk) K070453

Page __ of